NCT06067100View on ClinicalTrials.gov

U-LABA/ICS Effects on Exercise Performance, Indacaterol

NARecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 15, 2024

Primary Completion Date

July 15, 2026

Study Completion Date

December 1, 2026

Conditions
Exercise Performance
Interventions
DRUG

Indacaterol and Mometasonefluroate (low dose)

Participants are administered 125 µg indacaterol + mometasonefluroate

DRUG

Placebo

Participants are administered placebo

DRUG

Indacaterol and Mometasonefluroate (high dose)

Participants are administered 500 µg indacaterol + mometasonefluroate

Trial Locations (1)

2100

RECRUITING

August Krogh Building, Copenhagen

All Listed Sponsors
lead

Morten Hostrup, PhD

OTHER